INM · InMed Pharmaceuticals Inc.
$1.33
-0.02 (-1.48%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-K filed Sep 9, 2026
Market Cap
$7.58M
Shares
5.49M
Volume · Oct 2
28.34K
Avg daily vol (3M)
916.81K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.33
Open$1.37
Day$1.33–1.39
52W close$0.62–2.46
Avg vol 30d71K
Short int16K · 0.3% float · 1.0d
Short vol12%
Last earningsJun 30, 2021
DataJan 2020–Oct 2026
Filing10-K · Sep 9
Up next
filed Sep 9, 2026
call held Jun 30, 2021
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.51M
Trailing 12 months
Net income (TTM)
−$12.56M
Trailing 12 months
Revenue growth YoY
-26.2%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+269.4%
Year over year · more shares
Price change (1Y)
-41.2%
Trailing year
Short interest
0.3%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Very Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−6%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
39%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+87%
trailing
YTD return
+25%
this year
Relative strength
+74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+122% holders QoQ · +13 funds added
Insider flow
Accumulating
Net +$151.5K over 90 days · 0% sells
Short interest
Falling
0.29% of float · ▼ -48.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
35%
expanding
EPS growth
+63%
Y/Y
Free cash flow
$-8.6M
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
39%
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+122% holders QoQ · +13 funds added
Insider flow
Accumulating
Net +$151.5K over 90 days · 0% sells
Short interest
Falling
0.29% of float · ▼ -48.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 39%
Range high $2
vs 200-day avg +13%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INM
this stock
InMed Pharmaceuticals Inc.
|
$7.58M | +25.5% | +7.5% | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INM | -3.6% | +0.0% | +86.5% | -2.2% | +25.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.4% | +0.5% | +74.4% | -3.1% | +12.6% |